Radiotherapy with heavy charged particles at Lawrence Berkeley Laboratory.
Since July 1975, 157 patients have been irradiated with heavy charged particles at the Lawrence Berkeley Laboratory in a Phase I-II clinical trial to study the usefulness of these particles in the irradiation of human cancers. The particles utilized have included helium, primarily of interest because of improved dose distributions with reduction of dose to adjacent normal tissues, and heavier particles such as carbon, neon and argon ions which have the additional potential of increased biologic effectiveness against the tumor, especially hypoxic tumor cells. Initial results with helium particles have been sufficiently good to warrant a Phase III randomized trial in carcinoma of the pancreas; in other tumor sites, and with other particles, Phase I -- Phase II studies are in progress. Although follow-up is short, control within the irradiated area in this heterogeneous group of patients appears at least as good as with current megavoltage irradiation and complications to date are acceptably low, warranting further studies with heavy charged particles.
D001128:Argon / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000532:radiotherapy; D002140:California; D002244:Carbon / Q000627:therapeutic use; D002830:Choroid Neoplasms / Q000532:radiotherapy; D004938:Esophageal Neoplasms / Q000532:radiotherapy; D006371:Helium / Q000627:therapeutic use; D006801:Humans; D007477:Ions; D008545:Melanoma / Q000532:radiotherapy; D009356:Neon / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000532:radiotherapy; D010315:Particle Accelerators; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy; D012062:Relative Biological Effectiveness; D012867:Skin / Q000528:radiation effects
D007477:Ions; D006371:Helium; D009356:Neon; D001128:Argon; D002244:Carbon